New diabetes drug promising results

New diabetes drug aleglitazar is achieving good results in a phase II SYNCHRONY study that will be published in the Lancet, and presented to the American Diabetes Association Scientific Sessions. The new type 2 diabetes treatment may be safe and effective.
The drug is part of a class called PPAR co-agonists, similar in function to drugs such as rosiglitazone and pioglitazone. Both drugs are efficient agents for blood glucose control amongst patients with type 2 diabetes .
The researchers reportedly said: “Importantly, aleglitazar seemed to be safe and well tolerated over the course of the 16-week study. The sample size of this study was too small to make definitive conclusions, but that no heart attack or stroke events occurred is reassuring. By contrast, excess cardiovascular events have been noted for patients given muraglitazar and rosiglitazone after a fairly short exposure to treatment. The favourable balance in the safety and efficacy profile of aleglitazar represents encouraging short-term clinical data for this agent and provides good evidence to enter phase III investigation. It will be particularly interesting to see whether the combined beneficial glucose and lipid effects will translate into a benefit on cardiovascular outcomes.”